Protein expression of CXCL5/CXCR2 and CXCL12/CXCR4 were decreased with KT treatment, resulting in KT inhibiting cancer cells’ secondary growth within the bone (Figure 3E–I). The gene discussed is CXCR2; the disease is cancer.